PepGen Inc. (PEPG )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol PEPG
- Company PepGen Inc.
- Price $2.62
- Changes Percentage 4.8
- Change 0.12
- Day Low $2.4
- Day High $2.66
- Year High $19.3
- Year Low $1.16
- Market Cap $85,817,513
- Price Avg 50 EMA (D) $2.25
- Price Avg 200 EMA (D) $8.42
- Exchange NASDAQ
- Volume 316,170
- Average Volume 2,997,105
- Open $2.53
- Previous Close $2.5
- EPS -2.85
- PE -0.92
- Earnings Announcement 2025-05-12 10:59:00
- Shares Outstanding $32,692,386
Company brief: PEPGEN INC. (PEPG )
- Healthcare
- Biotechnology
- Dr. James G. McArthur Ph.D.
- https://www.pepgen.com
- US
- N/A
- 05-06-2022
- US7133171055
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
PEPG Corporation News
PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
businesswire.com -- BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...